ANANDA 207607

ANDA APPROVAL/TENTATIVE APPROVAL

Mylan Technologies Inc.
781 Chestnut Ridge Road
P.O. Box 4310
Morgantown, WV 26504
Attention: Bradley Davis
Head of Regulatory Science

Dear Sir:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on June 18, 2014, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg.

Reference is also made to the complete response letter issued by this office on May 9, 2018, and to any amendments thereafter.

We have completed the review of this ANDA, and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. The Office of Bioequivalence has determined your Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Suboxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, of Indivior Inc. (Indivior).

However, we are unable to grant final approval to your Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg, at this time because of the exclusivity issue noted below. Therefore, your ANDA is approved insofar as it pertains to Buprenorphine and Naloxone Sublingual Film, 12 mg/3 mg. Your Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg, is tentatively approved. This determination is based upon information available to the Agency at this time (e.g., information in your ANDA and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacturing and testing of the drug product). This determination is subject to change on the basis of new information that may come to our attention.

The RLD upon which you have based your ANDA, Indivior’s Suboxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency’s publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”):

<table>
<thead>
<tr>
<th>U.S. Patent Number</th>
<th>Expiration Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>8,017,150 (the ’150 patent)</td>
<td>February 13, 2023</td>
</tr>
<tr>
<td>8,475,832 (the ’832 patent)</td>
<td>March 26, 2030</td>
</tr>
<tr>
<td>8,603,514 (the ’514 patent)</td>
<td>April 3, 2024</td>
</tr>
<tr>
<td>9,687,454 (the ’454 patent)</td>
<td>August 7, 2029</td>
</tr>
<tr>
<td>9,855,221 (the ’221 patent)</td>
<td>February 14, 2022</td>
</tr>
<tr>
<td>9,931,305 (the ’305 patent)</td>
<td>February 14, 2022</td>
</tr>
</tbody>
</table>
Your ANDA contains paragraph IV certifications to each of the patents under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg and 12 mg/3 mg, under this ANDA. You have notified the Agency that Mylan Technologies Inc. (Mylan) complied with the requirements of section 505(j)(2)(B) of the FD&C Act and that litigation was initiated within the statutory 45-day period against Mylan for infringement of the '150, '832, and '514 patents in the United States District Court for the District of Delaware [Indivior Inc., Indivior UK Limited, and Monosol RX LLC v. Mylan Technologies Inc., Mylan Pharmaceuticals Inc., and Mylan N.V., Civil Action No. 15-1016] and in the United States District Court for the Northern District of West Virginia [Indivior Inc., Indivior UK Limited, and Monosol RX LLC v. Mylan Technologies Inc., Mylan Pharmaceuticals Inc., and Mylan N.V., Civil Action No. 15-0209], and that litigation was also initiated for infringement of the '454 patent in the United States District Court for the Northern District of West Virginia [Indivior Inc. and Indivior UK Limited v. Mylan Technologies Inc., Mylan Pharmaceuticals Inc., and Mylan N.V., Civil Action No. 17-0157].

With respect to Civil Action No. 15-1016, you have notified the Agency that on December 16, 2016, the court entered a Consent Decree and Final Judgment in favor of Mylan, finding non-infringement of the '832 patent. On May 4, 2017, the court entered a second Consent Decree and Final Judgment in favor of Mylan, finding non-infringement of the '150 patent. On September 27, 2017, this case was dismissed pursuant to a consent judgment.

With respect to Civil Action Nos. 15-0209 and 17-0157, you have notified the Agency that these cases were dismissed.

However, we are unable to grant final approval to your Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg, at this time. Prior to the submission of your ANDA, another applicant or applicants submitted a substantially complete ANDA providing for Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg, and containing a paragraph IV certification. Your ANDA will be eligible for final approval on the date that is 180 days after the commercial marketing date identified in section 505(j)(5)(B)(iv) of the FD&C Act.

Upon the foregoing, your ANDA is approved in so far as it pertains to Buprenorphine and Naloxone Sublingual Film, 12 mg/3 mg. Your Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg, is tentatively approved.

I. Approval of Buprenorphine and Naloxone Sublingual Film, 12 mg/3 mg

Under section 506A of FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

RISK EVALUATION AND MITIGATION STRATEGY (REMS) REQUIREMENTS

Section 505-1 of the FD&C Act authorizes FDA to require the submission of a risk evaluation and mitigation strategy (REMS), if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks [section 505-1(a)]. In accordance with section 505-1(i) of the FD&C Act, a drug that is the subject of an ANDA under section 505(j) is subject to certain elements of the REMS required for the applicable listed drug.

The details of the REMS requirements were outlined in our REMS notification letter dated September 21, 2015. In that letter, you were also notified that pursuant to section 505-1(i) of the
FD&C Act, a drug that is the subject of an ANDA and the listed drug it references must use a single, shared system for elements to assure safe use (ETASU), unless FDA waives that requirement.

Your final proposed REMS, December 21, 2017; is approved, and will be posted on the FDA REMS website: http://www.fda.gov/rems

The REMS consists of a Medication Guide, ETASU, and an implementation system.

Your REMS must be fully operational before you introduce Buprenorphine Hydrochloride and Naloxone Hydrochloride Sublingual Film into interstate commerce.

The Buprenorphine Transmucosal products for Opioid Dependence REMS uses a waiver-granted shared system for the ETASU and the REMS assessments. This waiver-granted shared system REMS currently includes the products listed on the FDA REMS website available at http://www.fda.gov/rems. Other products may be added in the future if additional NDAs or ANDAs are approved.

Under section 505-1(g)(2)(C) of the FD&C Act, FDA can require the submission of a REMS assessment if FDA determines an assessment is needed to evaluate whether the REMS should be modified to ensure the benefits of the drug outweigh the risks or to minimize the burden on the healthcare delivery system of complying with the REMS.

We remind you that you must include an adequate rationale to support a proposed REMS modification for the addition, modification, or removal of any goal or element of the REMS, as described in section 505-1(g)(4) of the FD&C Act.

We also remind you that section 505-1(f)(8) of the FD&C Act prohibits holders of an approved covered application from using any element to assure safe use to block or delay approval of an application under section 505(b)(2) or (j). A violation of this provision in 505-1(f) could result in enforcement action.

Prominently identify any submission containing a REMS assessment or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

ANDA 207607 REMS ASSESSMENT

NEW SUPPLEMENT FOR ANDA 207607/S-000
CHANGES BEING EFFECTED IN 30 DAYS
PROPOSED MINOR REMS MODIFICATION

or

NEW SUPPLEMENT FOR ANDA 207607/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED MAJOR REMS MODIFICATION

or
NEW SUPPLEMENT FOR ANDA 207607/S-000
PRIOR APPROVAL SUPPLEMENT
PROPOSED REMS MODIFICATIONS DUE TO SAFETY LABELING CHANGES
SUBMITTED IN SUPPLEMENT XXX

Should you choose to submit a REMS revision, prominently identify the submission containing the REMS revisions with the following wording in bold capital letters at the top of the first page of the submission:

REMS REVISION FOR ANDA 207607

To facilitate review of your submission, we request that you submit your proposed modified REMS and other REMS-related materials in Microsoft Word format. If certain documents, such as enrollment forms, are only in PDF format, they may be submitted as such, but the preference is to include as many as possible in Word format.

SUBMISSION OF REMS DOCUMENT IN SPL FORMAT
In addition to submitting the proposed REMS as described above, you can also submit the REMS document in Structured Product Labeling (SPL) format. If you intend to submit the REMS document in SPL format, include the SPL file with your proposed REMS submission.

For more information on submitting REMS in SPL format, please email REMS_Website@fda.hhs.gov

REPORTING REQUIREMENTS

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Agency should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Agency in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling materials prior to publication or dissemination. Please note that these submissions are voluntary. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert (PI), Medication Guide, and patient PI (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705
Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf)).

You must also submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf). Information and instructions for completing the form can be found at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf). For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

**ANNUAL FACILITY FEES**

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the *Federal Register* notice announcing facility fee amounts.

All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at [http://www.fda.gov/ForIndustry/DataStandards/StructacedProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructacedProductLabeling/default.htm), that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at [http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf](http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf). The SPL will be accessible via publicly available labeling repositories.

**II. Tentative Approval of Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg**

Our decision to tentatively approve your Buprenorphine and Naloxone Sublingual Film, 8 mg/2 mg, is based upon information currently available to the Agency (i.e., date in your ANDA and the status of current good manufacturing practice (cGMP) of the facilities used in the
manufacture and testing of the drug product). This decision is subject to change on the basis of new information that may come to our attention.

RESUBMISSION

To request final approval, please submit an amendment titled “FINAL APPROVAL REQUESTED” with enough time to permit FDA review prior to the date you believe that your ANDA will be eligible for final approval. A request for final approval that contains no new data, information, or other changes to the ANDA generally requires a period of 90 days for Agency review. Accordingly, such a request for final approval should be submitted no later than 90 days prior to the date on which you seek approval. A request for final approval that contains substantive changes to this ANDA or changes in the status of the manufacturing and testing facilities’ compliance with cGMPs will be classified and reviewed according to OGD policy in effect at the time of receipt. Applicants should review available agency guidance for industry related to amendments under the generic drug user fee program to determine the duration of Agency review needed to review the changes submitted. The submission of multiple amendments prior to final approval may also result in a delay in the issuance of the final approval letter.

The amendment requesting final approval should provide the legal/regulatory basis for your request for final approval and should include a copy of a court decision, settlement or licensing agreement, or other information described in 21 CFR 314.107, as appropriate. It should also identify changes, if any, in the conditions under which the ANDA was tentatively approved, i.e., updated information such as final-printed labeling, chemistry, manufacturing, and controls data as appropriate. This amendment should be submitted even if none of these changes were made, and it should be designated clearly in your cover letter as a “MINOR/MAJOR AMENDMENT TO ORIGINAL #2 – FINAL APPROVAL REQUESTED.”

In addition to the amendment requested above, the Agency may request, at any time prior to the date of final approval, that you submit an additional amendment containing information as specified by the Agency. Failure to submit either or, if requested, both types of amendments described above may result in a delay in the issuance of the final approval letter.

This drug product may not be marketed without final Agency approval under section 505(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under section 301 of the FD&C Act. Also, until the Agency issues the final approval letter, this drug product will not be deemed approved for marketing under section 505(j) of the FD&C Act, and will not be listed in the Orange Book.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those
responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

In addition, we note that GDUFA requires that certain non-manufacturing sites and organizations listed in generic drug submissions comply with the self-identification requirement. The failure of any facility, site, or organization to comply with its obligation to self-identify and/or to pay fees when due may raise significant concerns about that site or organization and is a factor that may increase the likelihood of a site inspection prior to approval. FDA does not expect to give priority to completion of inspections that are required simply because facilities, sites, or organizations fail to comply with the law requiring self-identification or fee payment. Additionally, we note that the failure of any facility referenced in the application to self-identify and pay applicable fees means that FDA will not consider the GDUFA application review goal dates to apply to that application.

The Electronic Common Technical Document (eCTD) is CDER’s standard format for electronic regulatory submissions. Beginning May 5, 2017, ANDAs must be submitted in eCTD format and beginning May 5, 2018, drug master files must be submitted in eCTD format. Submissions that do not adhere to the requirements stated in the eCTD Guidance will be subject to rejection. For more information please visit: www.fda.gov/ectd.

For further information on the status of this ANDA or upon submitting an amendment to the ANDA, please contact Kimberly McCullough, Regulatory Project Manager, at (240) 402-9021.

Sincerely yours,

{See appended electronic signature page}

For Vincent Sansone, PharmD
Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

---

1 The Agency notes that the ’454, ’221, and ’305 patents were submitted to the Agency after submission of your ANDA. Litigation, if any, with respect to these patents would not create a statutory stay of approval.

2 Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).